Camber Capital Management LP Cure Vac N.V. Transaction History

Camber Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$2.31 - $4.99 $2.77 Million - $5.99 Million	-1,200,000 Reduced 68.57%	550,000 $1.87 Million
Q3 2023 Nov 14, 2023	BUY	$6.5 - $10.77 $1.87 Million - $3.1 Million	287,500 Added 19.66%	1,750,000 $12 Million
Q2 2023 Aug 14, 2023	BUY	$6.69 - $12.25 $1.42 Million - $2.6 Million	212,500 Added 17.0%	1,462,500 $15.2 Million
Q1 2023 May 15, 2023	BUY	$6.38 - $12.5 $7.98 Million - $15.6 Million	1,250,000 New	1,250,000 $8.71 Million

12.3M

164K

117K

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $538M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.